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A B S T R A C T
Background: Mal de debarquement syndrome is a medically refractory disorder characterized by chronic
rocking dizziness that occurs after exposure to passive motion. Repetitive transcranial magnetic stimu-
lation (rTMS) can acutely suppress the rocking dizziness but treatment options that extend the beneﬁt
of rTMS are needed.
Objectives: 1) To determine whether transcranial direct current stimulation (tDCS) added after rTMS can
extend the beneﬁt of rTMS; 2) to determine whether participants can safely perform tDCS at home.
Methods: Participants were given ﬁve days of rTMS (1 Hz right DLPFC/10 Hz left DLPFC in right-
handers, vice versa in left-handers), according to a previously piloted protocol. They received three days
of training on tDCS self-administration and were then randomized to either real or sham tDCS for four-
weeks (anode left DLPFC/cathode right DLPFC for right-handers, vice versa for left-handers).
Results: Twenty-three participants completed the study. Those who received real tDCS after rTMS showed
signiﬁcant improvements in the degree of rocking perception as measured by the MdDS Balance Rating
Scale and anxiety ratings by Week 4 of tDCS and a trend for improvement on the Dizziness Handicap
Inventory. Two rTMS non-responders responded well to subsequent open-label tDCS. Side effects were
mild and not different between real and sham tDCS. There were no episodes of skin burns in a group
total of 556 sessions of tDCS. Satisfaction was rated high.
Conclusions: Home-based tDCS can be performed safely and may be beneﬁcial in selected individuals.
Adequate teaching, automatic device safety features, and a good communications infrastructure are com-
ponents of successful home therapy.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Neuromodulation therapies that involve low levels of current
applied transcranially represent a powerful new option for treat-
ing a growing number of neurological and psychiatric disorders [1–4].
One form, transcranial direct current stimulation (tDCS), involves
directionally applied current through one or more anodes and cath-
odes [5,6]. Scientiﬁc interest in expanding neuromodulation programs
into the home environment has been gaining traction as larger scale
studies have shown safety and tolerability of transcranially applied
electrical current when monitored by investigators [7–9]. Cur-
rently, there is both a need to invest in studies that ﬁne tune the
application of these cranial electrical therapies as well to bring some
of the more promising beneﬁts into the clinical realm, especially
for patients who have been otherwise deemed to be “medically re-
fractory.” However, one obstacle in transitioning these therapies into
clinical care has been in the development of infrastructure and
methods to ensure safety and compliance of treatment given outside
of controlled research settings [10]. The excellent safety record of
tDCS sessions within research settings suggests that, with appro-
priate safeguards, these treatments might be safely administered
by patients at home [11]. Public perception of tDCS has been shift-
ing toward growing acceptance of brain stimulation for either
treatment of symptoms or for personal enhancement, but there are
still challenges in striking a balance between freedom and control
in making these treatments more generally accessible [12]. Herein
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we describe our experience with administering a home-based tDCS
program for a disorder calledmal de debarquement syndrome (MdDS),
a disorder induced and exacerbated by travel with high morbidity
and limited treatment options [13]. The exploration of a home-
based tDCS program for MdDS represents a unique opportunity from
a beneﬁt to risk standpoint of translating transcranial electrical
therapy into the home environment and can serve as a case study
in how a home-based program can be managed.
MdDS is characterized by chronic rocking dizziness that occurs
after prolonged exposure to oscillating motion, such as occurs on
a boat, plane, or automobile [13]. Short periods of self-motion per-
ceptions that occur after exposure to passive motion have been
described in over 70% of healthy young individuals, but they rarely
last more than two days [14–16]. However, in some individuals, the
symptoms can last for months or years leading to signiﬁcant dis-
ability [17,18]. Re-exposure to passive motion, such as when the
individual is driving a car, ﬂying in a plane, or getting back on the
boat, temporarily relieves the internal feeling of rocking motion
[13,19]. Unfortunately, once the external motion stops the inter-
nal motion perception returns and is often worse than baseline.
Treatment options for MdDS are extremely limited and symptoms
that last longer than six months only occasionally resolve on
their own [17,20]. Prior efforts of applying different forms of
neuromodulation by either repetitive transcranial magnetic stim-
ulation (rTMS) or a vestibular-ocular reﬂex re-adaption paradigm
have been confounded by treatment effects being reversed by the
participant traveling back home [21].
In a prior study, we determined that 10Hz repetitive transcranial
magnetic stimulation (rTMS) to the dorsolateral prefrontal cortex
(DLPFC) opposite the dominant hand, or 1Hz rTMS to the DLPFC ip-
silateral to the dominant hand, could temporarily reduce the rocking
dizziness of MdDS [22]. In this study, the lateralization of treatment re-
sponse was quite pronounced in that left-handed participants were
worsened by l0Hz left DLPFC stimulation but were signiﬁcantly ben-
eﬁtted by 10Hz right DLPFC stimulation. Both open-label and sham-
controlled studies using amodiﬁed version of this rTMS protocol have
showneﬃcacy in acutely reducing the rockingperception [23,24]. Finally,
a double-blind placebo controlled trial of ﬁve days of 10Hz left DLPFC
stimulation in right-handed individuals has shown eﬃcacy signiﬁ-
cantly beyond the treatment period but with eventual return of
symptoms (Cha et al. in press Otol Neurotol [25]).
Because MdDS is a travel related disorder, we were faced with
the challenge of providing a neuromodulation treatment that may
extend the beneﬁt of rTMS but be manageable in the home envi-
ronment. Our goals in this study therefore were to determine the
following: 1) whether the addition of tDCS after an induction treat-
ment with ﬁve days of rTMS could prolong the improvement seen
with rTMS, 2) whether participants could apply the tDCS sessions
on themselves safely, and 3) what user interface issues are impor-
tant in treatment compliance and user satisfaction. We used our
previously determined rTMS protocol, switching the sides of stim-
ulation for left-handed participants [22–24]. This was an exploratory
single-blind sham-controlled study designed to determine feasi-
bility for remotely supervised tDCS treatments that could be used
for larger scale studies. The main outcome measure was the Diz-
ziness Handicap Inventory [26] with the MdDS Balance Rating Scale,
and the Hospital Anxiety and Depression Scale [27] being second-
ary measures.
Methods
IRB and consent
Study procedures were completed according to Declaration of
Helsinki guidelines and were approved by Western Institutional
Review Board (www.wirb.com). Participants provided written in-
formed consent. The original approval number for this study was
1140088 and the follow-up study to this trial is listed with Clini-
cal Trials identiﬁer: NCT02540616. The study was conducted from
September 2013 to June 2015 and all on-site study procedures were
performed at the Laureate Institute for Brain Research in Tulsa, OK.
The investigators have no ethical or ﬁnancial conﬂict of interests
with respect to the manufacturers of any of the equipment used in
the study.
Participant characteristics
Participants were recruited through web based postings on the
MdDS Balance Foundation website (www.mddsfoundation.org).
Inclusion criteria included the following: 1) a chronic perception
of rocking dizziness that started within two days after disembark-
ing from sea, air, or land based travel; 2) symptoms lasting
at least six months; 3) no other diagnosis determined after evalu-
ation by a neurologist or otolaryngologist with appropriate testing
to rule out peripheral inner ear or other central nervous system
cause for symptoms. Potential participants were excluded for the
following: 1) unstable medical or psychiatric condition (e.g. mania
or psychosis), 2) pregnant or planning to become pregnant during
study enrollment, and 3) contraindications to receiving rTMS
or undergoing a structural MRI scan (ferromagnetic or coiled
metal implants), and 4) any skin disorder that compromised skin
integrity over the scalp. In order to maximize the beneﬁt-to-risk
ratio of participation, participants who were not aware of other
medical alternatives were informed of these alternatives before
being consented.
Because of the rarity of the disorder, participants either drove
in from over four hours or ﬂew in from at least two hours away to
receive rTMS treatment and tDCS teaching in our laboratory. Par-
ticipants were required to identify a “Study Buddy” to provide back-
up communication with the study staff if communication was lost
and who would aid in observing the stimulation site for irritation
during the home tDCS phase.
MRI and rTMS
Participants underwent a magnetization-prepared rapid acqui-
sition with gradient echo scan on a GE Discovery MR750 3T whole-
body scanner (GE Healthcare, MilwaukeeWI, USA) for the purposes
of neuronavigation during the TMS sessions. Each participant un-
derwent ﬁve sessions of rTMS on consecutive days. The Localite TMS
Navigator (Localite GmBH, Germany) frameless stereotaxy system
was used for neuronavigation to identify the center of the DLPFC
in the middle frontal gyrus. rTMS was performed with the
Magventure MagPro X100 stimulator with a cooled ﬁgure-of-
eight coil in biphasic mode and the handle back at a 45 degree angle
relative to the mid-sagittal plane. Motor thresholds (MT) were de-
termined each day with independent measurements made for both
the right and left M1 hand areas. MTs were deﬁned as the percent
intensity of the stimulator output that generated a 50 μV motor
evoked potential in the contralateral abductor pollicis brevis muscle
in 50% of trials. rTMS sessions consisted of 1 Hz right DLPFC stim-
ulation at 110% of MT for 1200 pulses followed by 10 Hz left DLPFC
stimulation at 110% MT for 2000 pulses for right-handed partici-
pants, but the opposite for left-handed participants (i.e. 1 Hz left
DLPFC followed by 10Hz right DLPFC) according to our previous pro-
tocol determined for left-handed participants [22,24]. The 10 Hz
protocol was administered as trains of 40 pulses over four-seconds
followed by 26 seconds of rest.
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tDCS machine
The Transcranial Technologies tDCS machine (www.trans-
cranial.com) was used for the study. Password protected settings
were as follows: maximum current = 1 mA, ramp up time = 30-
seconds, duration = 20-minutes, maximum resistance = 15k ohms.
The sham mode consisted of 60 seconds of real stimulation given
at the beginning of the session with a ramp down. Pseudo current
and resistance outputs were presented on the screen in the sham
mode to simulate real stimulation.
tDCS capping
Each participant was custom ﬁt with a neoprene cap that had
snap electrodes placed over the region of the DLPFC as deter-
mined from their MRI (Fig. 1). A second elastic band was placed over
the sponges if needed to help maintain good scalp contact, which
was often needed for participants with thick hair. Participants were
instructed to center the headband so that the midline locators were
on the vertex and in the middle of the forehead and the horizon-
tal band was just above the eyebrows and over the ears. All anode
related connections were labeled red and all cathode related con-
nections were labeled black. Electrode housings of 5 × 7 cm were
designed by the investigator with die-cut Spontex sponges (Indus-
trial Commercial Supply, Cleveland, OH) held together by plastic
snaps. Anode and cathode sponges had opposite male and female
connections so that they could not be reversed. Participants were
providedwith saline solution (contact lens solution buffered to phys-
iologic pH and salt level) from a major manufacturer to wet the
sponges at home. Anodes were placed over the left DLPFC and cath-
odes over the right DLPFC in right-handed participants, and vice versa
for left-handed participants.
tDCS teaching
During their visit, the participants engaged in at least three face-
to-face teaching sessions of tDCS application (30–60 minutes each)
and were required to show that they could properly prepare and
apply the cap, start and stop the stimulation, troubleshoot, attach
and detach the cables, and store the device in the box. They were
instructed to not let any saline drip down the face or to excessive-
ly wet the hair. Since they were receiving rTMS during the same
week, they only completed about two-minutes of tDCS stimula-
tion each time they practiced. Written instructions with pictures
either in print form or through access to an electronic version on
the study server was provided as backup.
Randomization
All rTMS sessions were open label. tDCS sessions were random-
ized in a single-blindmanner to real and sham stimulations. Twenty-
four tDCS machines were set to real or sham settings at a ratio of
1:1 and placed in individual identical black boxes. The partici-
pants chose the boxes themselves to assure them of the
randomization. They performed their training sessions with the
machine that they selected. The devices themselves were labeled
with a code and only the research staff knew the key to the device
settings and the codes. After receiving ﬁve sessions of rTMS, par-
ticipants returned home and were instructed to complete ﬁve
sessions of tDCS per week for four weeks (20 sessions), not going
more than two days without a completing a session. After a four-
weekwashout period, the two groups were un-blinded and the sham
group was given the option of trying open label real tDCS for 4–12
weeks preceded by a new baseline assessment period and fol-
lowed by another washout period. Cap position was veriﬁed with
either the participant sending pictures of herself with the cap on
or via a webcam session with the study staff, whichever was pos-
sible for the participant.
Online tracking
Participants were given unique study identiﬁcations and a set
of personalized web links through SurveyMonkey®. A daily check-
in was required to report symptoms, e.g. “Today was a good day
because I got a lot of rest.” Data were time stamped and tracked
by the study staff daily. If two daily “check ins” were not done, the
participant was either emailed or called on the phone. The main
purpose of the daily check-in was to determine participant com-
pliance with the hypothesis that if they were conscientious in doing
the small things, they would be conscientious in doing the bigger
things. These notes also increased our understanding of symptom
modifying factors. The plan was for the Study Buddy to be con-
tacted if the participant did not respond to the study staff’s
communication efforts. A set of questionnaires was completed each
weekend with the main measures being the Dizziness Handicap In-
ventory (DHI) [26], MdDS Balance Rating Scale (MBRS), and the
Hospital Anxiety and Depression Scale (HADS) [27]. If the ques-
tionnaires were not completed by the followingMonday, a reminder
was sent.
The DHI is a well-validated 25-item scale of dizziness with a total
possible score of 100 points in which a score of 16–34 = mild hand-
icap, 36–52 = moderate handicap, and 54+ = severe handicap [26].
The HADS is a well-validated 14-item standard scale for measur-
ing depression and anxiety with each subcomponent scoring a
maximum of 21-points in which a score of 0–7 = normal, 8–10 = bor-
derline, and 11–21 = abnormal [27]. The MBRS is a 10-point scale
that solely assesses rocking perception designed so that scores six
and higher indicate impairedwalking (Supplementary Table S1). This
Figure 1. Cap model. A neoprene cap was custom ﬁt to each participant with elec-
trodes placed over the DLPFC as determined from the participant’s MRI. Anode
connections were in red; cathode connections were in black. Anode and cathode elec-
trodes were created with opposite cap attachments that could not be reversed.
539Y.-H. Cha et al. / Brain Stimulation 9 (2016) 537–544
scale was created by the lead investigator because there are no pub-
lished scales that speciﬁcally query about rocking dizziness. These
diaries were started 1–2 weeks before arrival to the study site as a
run-in phase to assess participant baseline and compliance.
Participant payment, side effects assessment, and survey
In order to probe the sensitivity of compliance of reporting to
study payment, the ﬁrst 12 participants (Group 1) recruited were
paid for each session of tDCS reported ($4/session) while the second
group of 12 participants (Group 2) was guaranteed payment for 20
sessions, regardless of how many they reported. Participants re-
ported each session of tDCS performed through their web links,
rating each side effect on a scale of 0–10, in which “0” was none
and “10” was intolerable. At the conclusion of the study, the par-
ticipants were asked to complete an anonymous non-compensated
survey of their experiences.
Statistical analysis
Data were analyzed with Stata IC version 14 (www.stata.com).
Mixed-effects repeated measures ANOVA analyses were per-
formed for each outcome measure with the between subject factor
being allocation to real versus sham tDCS and the within subject
factor being time. Data were ﬁt with a linear model with mean
change and predicted 95% conﬁdence intervals determined. Data
were not corrected for multiple comparisons since response at each
time point was highly correlated with response at subsequent time
points and did not meet criteria for independence. The main effect
of treatment allocation to real or sham for the 4-weeks of tDCS and
4-weeks of the washout period is reported. The interaction of time-
by-allocation is reported only if the main effect was signiﬁcant.
Signiﬁcance is considered for a two-tailed alpha of 0.05.
Results
Twenty-four women with the following characteristics partici-
pated in the study: 21 right-handed, three left-handed, mean
age ± s.d. = 52.9+ /12.2 years, range = 28–76 years; duration of symp-
toms ± s.d. = 33.8 ± 23.0 months, range = 8–96 months; triggers:
15 = water based travel (e.g. cruise), ﬁve = air travel, ﬁve = land travel
(train or car ride) (1 participant had combined boat/plane trig-
gers). Baseline symptom scores of participants allocated to real vs
sham tDCS are provided in Table 1, which showed no statistical dif-
ferences. Twenty-three of the 24 participants completed all ﬁve
sessions of rTMS. The remaining participant found rTMS too painful
even at <50% of her MT so she was removed from the study. The
very ﬁrst participant who completed rTMSwas given open-label tDCS
as our test subject for the online reporting set-up; her data were
analyzed with the open-label data. Of the remaining participants,
12 received real tDCS and 10 received sham tDCS. All 10 partici-
pants who had initially received sham stimulation were enrolled
in the open-label phase of which nine ﬁnished. Side effects of tDCS
are reported for all 23 participants who had performed any home
tDCS.
DHI
Scores on the DHI decreased but were not signiﬁcantly below
baseline immediately after rTMS (Fig. 2A). DHI scores increased after
travel for both real and sham tDCS groups but then normalized to
baseline with a non-signiﬁcant trend toward improvement noted
by Week 3 and 4 after real tDCS but not for sham tDCS. The four
week main effect of treatment allocation averaged over all post-
TMS time points was non-signiﬁcant, F(1,7) = 1.35, p = .247).
MBRS
Improvement in the MdDS Balance Rating Scale was noted im-
mediately after rTMS for both groups allocated to real or sham tDCS
(Fig. 2B). After an expected travel related exacerbation, the scores
gradually improved in the real tDCS group but gradually wors-
ened and plateaued in the sham group. There was a trend toward
decreasing MBRS scores between Weeks 2 and 3 and a signiﬁcant
decrease at Weeks 4 in the real tDCS group. The four week main
effect of treatment allocation averaged over all post-TMS time points
had a trend toward signiﬁcance, F(1,7) = 3.76, p = .054).
HADS
The Hospital Anxiety and Depression scores were divided into
the depression and anxiety components (Fig. 2C and D). Depres-
sion scores worsened in the week after travel home but plateaued
to baseline with real tDCS. During sham tDCS, the depression scores
worsened and remained elevated until the washout phase. There
were no signiﬁcant improvements in depression over baseline in
either group. The main effect of treatment allocation was non-
signiﬁcant, F(1,7) = 0.77, p = .380). Anxiety scores decreased in the
real tDCS groups by Week 4 but not in the sham tDCS group. The
four weekmain effect of treatment allocation averaged over all post-
TMS time points was non-signiﬁcant, F(1,7) = 1.72, p = .192).
Open label tDCS
All ten participants who underwent sham stimulation elected
to try real tDCS for at least four weeks followed by a four-week
washout period. In order to directly compare the responses against
the randomized real and sham group, only the ﬁrst four weeks of
responses to open-label tDCS were analyzed if the participant did
more than four-weeks of open-label tDCS,
One participant who had had progressively worsening symp-
toms while she was on sham tDCS felt worse several hours after
one session of real tDCS so further sessions were stopped. Her symp-
toms continued to worsen for manymonths despite no further tDCS.
Her data were not included in the analysis because she had only
done one session of tDCS. For the participant who completed only
threeweeks of tDCS, we performed a last observation carried forward
analysis using her Week 3 scores as her Week 4 scores. She com-
pleted all four-weeks of the washout phase.
There was a greater immediate decrease in the DHI and MBRS
scores at tDCS Week 2 with open-label tDCS compared to treat-
ment after rTMS, perhaps owing to the lack of a preceding travel
related exacerbation (Fig. 2, green lines). On a group level the im-
provements were modest. However, one participant, who had not
Table 1
Baseline symptom scores of participants randomized to real or sham tDCS.
Scale Baseline (s.d.) p-Value
DHI
Real 49.67 (19.10) 0.578
Sham 53.80 (13.80)
MBRS
Real 5.00 (1.04) 0.634
Sham 5.30 (1.83)
HADS-Depression
Real 9.25 (3.62) 0.588
Sham 8.50 (2.55)
HADS-Anxiety
Real 6.67 (5.42) 0.710
Sham 7.40 (3.17)
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responded to sham tDCS, went into complete remission within one
week of starting real tDCS. A second participant noted gradual im-
provement in her symptoms representing a ﬁve-point drop on the
MBRS scale over the course of eight-weeks with cyclical exacerba-
tions during the premenstrual phase of her menstrual cycle. Neither
of these two participants had responded to open-label rTMS despite
having strong responses to tDCS.
Compliance
Group 1was asked to perform one-week of daily pre-TMS “check-
in” reporting, amounting to 68 possible daily reports. They reported
an average of 65.4 [s.d. 6.5, range 51–68, median 66.5] reports. After
Group 1 completed the study, we increased the pre-TMS reporting
requirements to two-weeks, i.e. 75 possible daily reports. Group 2
participants reported an average of 74.7 [s.d. 3.2, range 69–78,
median 75] daily reports.
A total of 245 sessions of real tDCS and 186 sessions of sham
tDCS were reported in the randomization phase. An additional 311
sessions were reported by the sham participants when they crossed-
over to open-label real tDCS. One participant allocated to real
stimulation stopped after 12 sessions because of feeling “revved up,”
and two participants were allowed to do an extra 1-week and 2-
weeks of stimulation because they had to undergo unavoidable travel
during the post-TMS period. These three participants were removed
in the analysis of the effect of payment on stimulation sessions
reported.
There was a trend toward a difference in the number of ses-
sions reported when payment was guaranteed, but only when the
participants had been randomized to sham tDCS. Group 1 sham par-
ticipants reported a mean of 20.6 ± 1.1 sessions; Group 2 sham a
mean of 16.6 + /3.8 sessions, two tailed (p = 0.056, d.f. = 8). Though
only 20 sessions were required, some participants had performed
some extra tDCS sessions because of starting on a weekend. There
was no difference in sessions reported for real stimulation (Group
1 real reported 19.8 ± 1.8 sessions; Group 2 real 19.8 ± 1.5, two tailed,
p = 0.60, d.f. = 8).
Postage paid boxes had been provided to the participants when
they had ﬁrst arrived for their rTMS sessions. All stimulators and
accessories were returned undamaged at the end of the study.
Adequacy of blinding
The overall correct guess rate for the allocation was 12/22 (3 of
12 guessed correctly for real; 7 of 10 guessed correctly for sham).
The only reason for guessing “sham” regardless of actual alloca-
tion was because of a lower than expected treatment effect, even
if there had been some symptom improvement. This is because,
despite counseling, most participants had harbored some hope of
becoming completely symptom free. The reasons for guessing “real”
included treatment intensity and improved symptoms.
Side effects
Percentages of side effects at each level (0–10) were tabulated
for real and sham tDCS sessions (Table 2). These percentages were
entered into a two-sample Kolmogorov–Smirnov test for equality
of distributions. There were no differences between real and sham
Figure 2. Change in clinical outcome scores. Change in total DHI (A), MBRS (B), HADS Depression (C) and Anxiety (D) subscales relative to baseline immediately after rTMS
and during the four-week treatment and four-week washout periods. Real tDCS = blue line, sham tDCS = red line, open-label real tDCS = green line. Mixed-effects ANOVA
with a linear model and 95% conﬁdence interval for the mean predicted change at each time point was modeled with our data. Signiﬁcant reductions in scores at p < 0.05
at each time point are noted with an “*.”
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stimulation in the general side effect proﬁles (all p values for com-
parisons were >0.479).
Skin burns and equipment failures
There were no instances of skin irritation or skin burns in either
the randomized or cross-over phases when stimulation was limited
to 1.0 mA, even after 60 sessions of tDCS over 12 weeks in one par-
ticipant. However, one participant who had had no improvement
at 1.0 mA in the randomization phase was gradually ramped up to
2.0 mA in the open-label phase with guidance from the study staff
to determine whether treatment intensity was a limiting factor. After
11 days of stimulation at 2.0 mA (total 31 sessions), she noticed a
painless area of skin irritation under the anode. She was in-
structed to stop stimulation due to the risk of current shunting
through the lesion. She recovered without any other incidents.
Participant survey
Twenty-two of the 23 participants completed the post study
survey. Questionnaires were asked in both a positive manner and
the inverse asked in a negative manner with a random presenta-
tion. For the purposes of data reporting, questions about related
features are grouped (Table 3). The overall sense of convenience,
conﬁdence, and adequacy of instruction was high with three people
expressing that more instruction would have been helpful but 14
participants expressing that more instruction would not have been
helpful and possibly burdensome.We speciﬁcally queried how com-
fortable the participants would be in performing tDCS without the
guidance of a physician, and themajority felt quite comfortable. Both
of the participants who indicated that they would be “very uncom-
fortable” were in the 60–69 year age range. Eight participants felt
beneﬁted by tDCS while 11 did not. The others remained neutral.
Most participants expressed a likelihood of participating in future
brain stimulation studies.
Six of the study participants eventually purchased their own
stimulators directly from themanufacturer and continued to perform
either regular or intermittent stimulation on themselves with either
guidance from their own physicians or through continued contact
with the study staff.
Discussion
Our study explored the feasibility of administering a remotely
monitored tDCS treatment program for a balance disorder. Overall,
the compliance level was high and safety was excellent. As treat-
ment effects increased with longer treatment duration, it is possible
that if we had extended the initial treatment phase to beyond four
weeks, more substantial effects may have been noted. Treatment
with open-label tDCS did not suffer from the travel related exac-
erbation that occurred after the rTMS portion. However, participants
who received open-label tDCS after un-blinding did not beneﬁt from
an induction treatment with rTMS that was immediately followed
by maintenance treatment with tDCS. Therefore, our study design
Table 2
Percentage of ratings for each side effect and intensity level.
Tingling Itching Redness Headache Tiredness Confusion Nausea Other
Rating Real Sham Real Sham Real Sham Real Sham Real Sham Real Sham Real Sham Real Sham
0 20 23 67 97 96 98 90 81 73 85 95 95 99 95 95 100
1 41 24 19 2 2 1 8 4 11 3 4 5 1 4 2 0
2 12 26 9 1 1 0 1 4 8 5 1 0 0 0 2 0
3 11 16 2 0 0 1 0 1 3 2 1 0 0 0 0 0
4 6 2 1 0 0 1 1 1 2 1 0 0 0 0 0 0
5 7 2 2 0 1 0 0 5 2 1 0 0 0 1 0 0
6 4 6 1 0 0 0 0 3 2 1 0 0 0 0 0 0
7 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0
8 0 1 0 0 0 0 0 0 0 2 0 0 0 0 0 0
9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Table 3
Participant survey.
Statement Strongly
agree
Agree Neither agree
nor disagree
Disagree Strongly
disagree
N/A
The online diaries were convenient. 10 7 4 0 0 0
It was diﬃcult for me to use mobile and online tools. 0 3 2 11 5 0
I felt conﬁdent setting up the stimulation sessions. 11 9 2 0 0 0
The stimulation sessions were diﬃcult to set up. 0 3 1 7 9 1
I could ﬁnd a convenient time to do the stimulation sessions. 6 14 1 1 0 0
The stimulation sessions interfered with my everyday life. 0 3 6 7 5 1
I felt that I had enough in-person one-on-one instruction. 11 8 2 1 0 0
It would have helped to have more in-person one-on-one instruction. 1 2 4 11 3 1
I felt that I was paid enough for my time. 5 12 4 1 0 0
I would have participated without getting paid. 11 7 2 2 0 0
More instruction through Facetime/Skype would have been helpful. 0 1 4 8 2 6
More instruction through Facetime/Skype would have been burdensome. 0 2 8 2 3 7
I felt that the Facetime/Skype sessions were helpful. 8 6 0 0 0 8
Overall, I felt that transcranial electrical stimulation treatment beneﬁted me. 2 6 4 10 1 0
How comfortable would you be doing transcranial stimulation on your own
without having a physician overseeing your use?
Very
comfortable
Somewhat
comfortable
Neutral Somewhat
uncomfortable
Very uncomfortable
11 6 0 2 2
How likely are you to participate in a future brain stimulation study? Very likely Likely Not sure Unlikely Very unlikely
13 4 3 1 1
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also revealed the eﬃcacy of tDCSwithout an rTMS induction. Though
the group effects were modest, the individual effects could be
quite substantial. Given the safety and ease of this form of
neuromodulation, either primary or adjunctive tDCS treatment for
MdDS may be reasonable especially because so few treatment
options that do not involve travel exist for this disorder.
We included several assurances within the study design to min-
imize inadvertent harm to the participant. These measures included
1) stimulation with a personally ﬁtted cap, 2) password protected
tDCS device settings, 3) regular symptom reporting and commu-
nication with study staff, 4) enlisting backup help from a ‘Study
Buddy.’ Though it was never necessary to contact the Study Buddy,
we have included the Study Buddy in the formal consent process
in future iterations of this project, and 5] the online reporting tool
which was instrumental in allowing the investigators to receive
timely feedback.
There were several factors that aided in our high compliance rate.
Primarily, MdDS is an intractable disorder with very limited treat-
ment options. This increased the sense of personal investment by
the participants. Second, the research staff spent a signiﬁcant amount
of time (~20-hours) with each participant during their visits. This
led to the recognition of mutual commitment to the reliability of
the data, participant safety, and care for the equipment. Third, the
participants and study staff maintained close communication
throughout the stimulation period with occasional cues to com-
plete data forms. This acted as a gentle reminder that the staff was
following the participant’s clinical course despite being at a distance.
Three tDCS training sessions were more than adequate for the
majority of the participants, with more potentially being burden-
some. However, occasional participants anonymously expressed
needingmore guidance even if they had initially demonstrated com-
petence and expressed feeling conﬁdent with the procedure. A few
participants did express frustration with getting just the area under
the sponges wet with saline noting that the devices would not let
them start stimulation without adequate dampness. This is a
common issue even with supervised tDCS sessions but partici-
pants, who have far less experience than researchers, have a lower
frustration tolerance for devices when they do not launch. We tried
to address some of these issues by initiating webcam or Facetime®
sessions with the participants when we received some of this feed-
back. We were able to initiate “face-to-face” trouble-shooting over
a webcam for participants in Group 2, which helped address some
of these issues.
In this pilot study we were concerned about adequate blinding
and safety and thus limited the treatment intensity to 1 mA, an in-
tensity level that is conducive to blinding [28]. Theoretically more
robust treatment effects may have been attained with higher treat-
ment intensity, however. The password protected locked settings
on the tDCS device prohibited the participants from tinkering with
the controls making inadvertent dosage increases unlikely. Through
our educational sessions, we tried to instill in the participants an
understanding that even if a little stimulation is good, more is not
always better and may contribute to more side effects. With good
participant screening, any suggestion of skin irritation requiring stop-
ping treatment was communicated immediately. Other side effects
were well within the realm of what have been typically reported
for cranial electrical stimulation sessions [7,11].
Because we hadmade personalized caps for the participants, they
could not let anyone else use the caps. Additionally, our partici-
pant population was an educated group of middle-aged women,
most of whom had professional careers, were free frommajor psy-
chiatric disorders, and were generally in supportive relationships
within their families. Application of home-based tDCSwithin a larger
ﬁeld of clinical syndromes would have to be done with additional
precautions when using “one size-ﬁts-all” cap designs, treatment
of younger individuals, those with less stable medical conditions,
cognitive challenges, or who do not have good family or peer support.
In the clinical realm, face-to-face follow-up appointments, enlist-
ing additional help from a Study Buddy to remove the device if
abused, and establishingmethods to remotely deactivate the devices
may be additional safeguards when home-based cranial electrical
therapy becomes more widely administered. We note that the left
anodal/right cathodal tDCS montage is being used in a study of
bipolar disorder whichwill test whether this montagemight unmask
mania in individuals who have an underlying vulnerability to mood
ﬂuctuations [29].
A limitation to our study was that since we could not track the
actual use of the device, we could not be certain that the devices
were actually being used. Since most cranial electrical stimulation
work still lies within the realm of research, we did try to deter-
mine whether extraneous factors like payment would affect
compliance with reporting. Deception could not be ruled (report a
session but not actually do the session) but we felt that this was
unlikely given the modest payment level. Compliance of reporting
during the run-in phases was extremely high indicating a fairly high
level of conscientiousness.
Conclusion
Our study shows that many stimulation sessions of tDCS can be
performed safely and effectively by non-professionals when they
are adequately trained, have reasonable safeguards in place, and are
closely followed. Although the treatment effects were modest and
confounded by the travel effect, about a third of the participants felt
beneﬁted from tDCS and a quarter continued to use tDCS post study,
even intermittently. This is a large proportion considering that MdDS
symptoms are quite resistant to treatment particularly when they
pass six-months of duration [17]. Some advantages of this therapy
are its relative ease of use, ﬂexibility, low cost, and the promotion
of a sense of self-eﬃcacy in actively participating in treatment.
Ongoing assessment of competence and incorporation of partici-
pant feedback may promote effective long-term usage. We also note
that two people who did not have a response to rTMS did have a
signiﬁcant response of tDCS, despite the caveat that it was in the
open-label phase. Presently in the United States, tDCS is used off-
label, through an ethics committee approved compassionate care
pathway, or through the auspices of a clinical trial [30]. The rela-
tive beneﬁt to risk ratio will be unique to each particular patient
group but advancing technology may alter this ratio for patients in
general. Although self-administered tDCS may not be appropriate
for all individuals, careful selection and monitoring may allow this
therapy to become more widely available and help redeﬁne the
concept of medical refractoriness.
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